drugset
drugset / Trial / NCT05021666

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study

NCT05021666 ↗

Phase 1 Completed 82 enrolled PegBio Co., Ltd. Covance · collab
RandomizedSequentialTriple-blindTreatment

Summary

This will be a randomized, double-blind, placebo-controlled, single- and multiple SC dose escalating study conducted in 2 parts.

Timeline

Start
2020-07-29
Primary completion
2022-05-18
Completion
2022-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PB-718 Unknown — Subcutaneous

Indications

No indication recorded.